Polymer Factory Sweden AB
NNGM:POLYMER0.52
SEK
+0.00
(-0.76%)
ISIN
SE0015244470
Return %
Stock
S&P 500
1Y
-42.64
14.20
3Y
- -
81.12
5Y
- -
68.34
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.Company Description
- CEO
- Mats Christer Wallnér
- Full Time Employees
- 3
- Sector
- Process industries
- Industry
- Chemicals: specialty
- Address
- Stockholm Sweden
- IPO Date
- Apr 7, 2021
- Website
- polymerfactory.com
- Similar Companies
- Business
- Polymer Factory Sweden AB is a Sweden-based biotechnology and materials science company that develops, manufactures, and commercializes dendritic nanotechnologies and dendritic polymer materials for the life science, pharmaceutical, biotechnology, and chemical industries. Founded in 2006 as a spin-out from the KTH Royal Institute of Technology and headquartered in Stockholm, Sweden, the company is listed on the Nordic Growth Market (NGM) under the ticker POLYMER. Polymer Factory Sweden AB operates globally, serving academic research institutions, clinical diagnostic laboratories, and multinational pharmaceutical and biotechnology corporations across Europe, North America, and the Asia-Pacific region. The company operates through three principal technology segments: mass spectrometry calibration, dendritic drug delivery nanocarriers, and high-precision dendritic materials. Polymer Factory Sweden AB manufactures and supplies a comprehensive portfolio of dendritic products and specialized services, comprising SpheriCal, a proprietary portfolio of monodisperse dendritic calibrants engineered for MALDI-TOF (Matrix-Assisted Laser Desorption/Ionization Time-of-Flight) and ESI (Electrospray Ionization) mass spectrometry calibration standards across broad mass ranges; bis-MPA (2,2-bis(methylol)propionic acid) based dendrimers and dendrons with diverse surface functionalities, including hydroxyl, amine, carboxyl, and azido terminal groups for biomedical and diagnostic applications; BowtieD, multifunctional dendritic macromolecules designed for advanced bioconjugation, targeted drug delivery, and theranostic systems; dendritic hyperbranched polymers and multi-arm PEG architectures for polymeric biomaterials, tissue engineering, and coatings; and custom synthesis, formulation development, contract research, and analytical characterization services for specialized dendritic structures and bioconjugates. In recent developments, Polymer Factory Sweden AB has advanced its commercialization strategy through new global distribution partnerships, product portfolio enhancements, and capital reinforcement initiatives. The company expanded international market access for its SpheriCal mass spectrometry calibration line by entering into distribution and evaluation agreements with life science instrumentation providers and specialty reagent distributors in North America and Europe. To support commercial scale-up and accelerate research and development of its bioconjugation and therapeutic delivery platforms, the company completed capital raising transactions through rights issues of units and warrants. Operationally, Polymer Factory Sweden AB continues to expand its intellectual property estate covering dendritic architectures and mass spectrometry standards while broadening its product catalog with newly certified MALDI and ESI calibration kits to meet increasing regulatory and precision requirements in high-throughput proteomic, lipidomic, and synthetic polymer analysis workflows.